Nuclear Medicine Procedures for Treatment Evaluation and Administration

  1. Arbizu, Javier 1
  2. Rodriguez-Fraile, Macarena 1
  3. Martí-Climent, Josep M 1
  4. Domínguez-Prado, Inés 1
  5. Vigil, Carmen 1
  1. 1 Clínica Universitaria de Navarra

    Clínica Universitaria de Navarra

    Pamplona, España


Liver Radioembolization with 90Y Microspheres

Editorial: Springer-Verlag

ISSN: 0942-5373 2197-4187

ISBN: 9783642364723 9783642364730

Ano de publicación: 2014

Páxinas: 63-75

Tipo: Capítulo de libro

DOI: 10.1007/174_2013_863 GOOGLE SCHOLAR lock_openAcceso aberto editor


The 90Yttrium radioembolisation (RE) procedure requires the collaboration of a multidisciplinary team that includes hepatologists, oncologists, interventional radiologists and nuclear medicine specialists working together in close collaboration. To avoid toxicity to the patient, a thorough angiographic evaluation is performed to identify extrahepatic vessels that may feed the tumours (to guarantee efficacy). To mimic the microsphere application during the treatment, angiographic evaluation is accomplished with 99mTechnetium-labelled macroaggregated albumin injection into the vessel of interest, followed by imaging. Both procedures combined are essential to plan the RE therapy, and to detect and eventually occlude every collateral vessel arising from a hepatic artery that may carry microspheres to the gastrointestinal tract or other extrahepatic organs. Moreover, this approach permits the calculation of hepatopulmonary shunting, and tumour and liver tissue targeting. With this information taken together, the treatment is designed and activity is calculated to maximise the dose of radiation delivered to liver tumours while safely preserving the non-tumoural parenchyma.

Referencias bibliográficas

  • Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, Wilhelm K, Biersack HJ, Ezziddin S (2010) The significance of 99 mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med 51(8):1206–1212
  • Ahmadzadehfar H, Muckle M, Sabet A, Wilhelm K, Kuhl C, Biermann K, Haslerud T, Biersack HJ, Ezziddin S (2011) The significance of bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects. Eur J Nucl Med Mol Imaging 39:309–315
  • Ahmadzadehfar H, Sabet A, Meyer C, Habibi E, Biersack HJ, Ezziddin S (2012) The importance of tc-MAA SPECT/CT for therapy planning of radioembolization in a patient treated with bevacizumab. Clin Nucl Med 37(11):1129–1130
  • Bagni O, D’Arienzo M, Chiaramida P, Chiacchiararelli L, Cannas P, D’Agostini A, Cianni R, Salvatori R, Scopinaro F (2012) 90Y-PET for the assessment of microsphere biodistribution after selective internal radiotherapy. Nucl Med Commun 33(2):198–204
  • Bilbao JI, Garrastachu P, Herráiz MJ, Rodríguez M, Inarrairaegui M, Rodríguez J, Hernández C, de la Cuesta AM, Arbizu J, Sangro B (2010) Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors. Cardiovasc Interv Radiol 33(3):523–531
  • Campbell JM, Wong CO, Muzik O, Marples B, Joiner M, Burmeister J (2009) Early dose response to yttrium-90 microsphere treatment of metastatic liver cancer by a patient-specific method using single photon emission computed tomography and positron emission tomography. Int J Radiat Oncol Biol Phys 74(1):313–320
  • Carretero C, Munoz-Navas M, Betes M, Angos R, Subtil JC, Fernandez-Urien I, De la Riva S, Sola J, Bilbao JI, de Luis E (2007) Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol 102(6):1216–1220
  • Covey AM, Brody LA, Maluccio MA, Getrajdman GI, Brown KT (2002) Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology 224(2):542–547
  • Cremonesi M, Ferrari M, Bartolomei M, Orsi F, Bonomo G, Aricò D, Mallia A, De Cicco C, Pedroli G, Paganelli G (2008) Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment. Eur J Nucl Med Mol Imaging 35(11):2088–2096
  • D’Arienzo M, Chiaramida P, Chiacchiararelli L, Coniglio A, Cianni R, Salvatori R, Ruzza A, Scopinaro F, Bagni O (2012) 90Y PET-based dosimetry after selective internal radiotherapy treatments. Nucl Med Commun 33(6):633–640
  • Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, Hendler AL, Goin JE (2000) Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 41(10):1673–1681
  • Even-Sapir E, Keidar Z, Bar-Shalom R (2009) Hybrid imaging (SPECT/CT and PET/CT)–improving the diagnostic accuracy of functional/metabolic and anatomic imaging. Sem Nucl Med 39:264–275
  • Fabbri C, Sarti G, Cremonesi M, Ferrari M, Dia AD, Agostini M, Botta F, Paganelli G (2009) Quantitative analysis of 90Y bremsstrahlung SPECT-CT images for application to 3D patient-specific dosimetry. Cancer Biother Radiopharm 24(1):145–154
  • Flamen P, Vanderlinden B, Delatte P, Ghanem G, Ameye L, Van Den Eynde M, Hendlisz A (2008) Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with yttrium-90 labeled resin microspheres. Phys Med Biol 53(22):6591–6603
  • Ford KW (1955) Predicted 0+ level in 40Zr90. Phys Rev 98:1516–1517
  • Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, Poree P, Clement B, Raoul JL, Boucher E (2012) Dosimetry based on 99 mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med 53(2):255–263
  • Garin E, Rolland Y, Lenoir L, Pracht M, Mesbah H, Poree P, Laffont S, Clement B, Raoul JL, Boucher E (2011) Utility of quantitative tc-MAA SPECT/CT for yttrium-labelled microsphere treatment planning: calculating vascularized hepatic volume and dosimetric approach. Int J Mol Imaging. doi:10.1155/2011/398051
  • Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, Brans B, Lambert B, Konijnenberg M, Borson-Chazot F et al (2011) EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 38(7):1393–1406
  • Gulec SA, Mesoloras G, Dezarn WA, McNeillie P, Kennedy AS (2007) Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med 5:15
  • Gulec S, Sztejnberg M, Siegel J (2010) Hepatic structural dosimetry in 90Y microsphere treatment: a monte carlo modeling approach based on lobular microanatomy. J Nucl Med 51:301–310
  • Gupta A, Gill A, Shrikanthan S, Srinivas S (2012) Nontargeted Y-90 microsphere radioembolization to duodenum visualized on Y-90 PET/CT and bremsstrahlung SPECT/CT. Clin Nucl Med 37:98–99
  • Hamami ME, Poeppel TD, Müller S, Heusner T, Bockisch A, Hilgard P, Antoch G (2009) SPECT/CT with 99 mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med 50:688–692
  • Haug AR, Heinemann V, Bruns CJ, Hoffmann R, Jakobs T, Bartenstein P, Hacker M (2011) 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging 38:1037–1045
  • Ho S, Lau W, Leung T, Chan M, Ngar Y, Johnson P, Li A (1996) Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med Mol Imaging 23:947–952
  • Jha AK, Zade AA, Rangarajan V, Purandare N, Shah SA, Agrawal A, Kulkarni SS, Shetty N (2012) Comparative analysis of hepatopulmonary shunt obtained from pretherapy 99 mTc MAA scintigraphy and post-therapy 90Y bremsstrahlung imaging in 90Y microsphere therapy. Nucl Med Commun 33:486–490
  • Kao YH, Tan EH, Ng CE, Goh SW (2011) Yttrium-90 time-of-flight PET/CT is superior to bremsstrahlung SPECT/CT for postradioembolization imaging of microsphere biodistribution. Clin Nucl Med 36(12):186–187
  • Kao YH, Tan AEH, Burgmans MC, Irani FG, Khoo LS, Lo RHG, Tay KH, Tan BS, Chow PKH, Ng DCE (2012) Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization. J Nucl Med 53(4):559–566
  • Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A, Espat J, Bilbao JI, Sharma RA (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68(1):13–23
  • Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, Garafalo M, Liu D, Coldwell D, Savin M et al (2009) Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 74(5):1494–1500
  • Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R (2012) Radioembolization for the treatment of liver tumors: general principles. Am J Clin Oncol 35(1):91–99
  • Knesaurek K, Machac J, Muzinic M, DaCosta M, Zhang Z, Heiba S (2010) Quantitative comparison of yttrium-90 (90Y)-microspheres and technetium-99 m (99 mTc)-macroaggregated albumin SPECT images for planning 90Y therapy of liver cancer. Technol Cancer Res Treat 9(3):253–262
  • Lambert B, Mertens J, Sturm EJ, Stienaers S, Defreyne L, D’Asseler Y (2010) 99 mTc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres. Eur J Nucl Med Mol Imaging 37(12):2328–2333
  • Lau W, Leung T, Ho S, Chan M, Leung N, Lin J, Metreweli C, Li A (1994) Diagnostic pharmaco-scintigraphy with hepatic intraarterial technetium-99m macroaggregated albumin in the determination of tumour to non-tumour uptake ratio in hepatocellular carcinoma. Br J Radiol 67(794):136–139
  • Lau WY, Kennedy AS, Kim YH, Lai HK, Lee RC, Leung TW, Liu CS, Salem R, Sangro B, Shuter B et al (2012) Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 82(1):401–407
  • Lenoir L, Edeline J, Rolland Y, Pracht M, Raoul JL, Ardisson V, Bourguet P, Clement B, Boucher E, Garin E (2012) Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. Eur J Nucl Med Mol Imaging 39(5):872–880
  • Leong QM, Lai HK, Lo RG, Teo TK, Goh A, Chow PK (2009) Radiation dermatitis following radioembolization for hepatocellular carcinoma: a case for prophylactic embolization of a patent falciform artery. J Vasc Interv Radiol 20(6):833–836
  • Leung WT, Lau WY, Ho SK, Chan M, Leung NW, Lin J, Metreweli C, Johnson PJ, Li AK (1994) Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m macroaggregated albumin. J Nucl Med 35(1):70–73
  • Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, Metreweli C, Johnson PJ, Li AK (1995) Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33(4):919–924
  • Lhommel R, Goffette P, Van den Eynde M, Jamar F, Pauwels S, Bilbao JI, Walrand S (2009) Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur J Nucl Med Mol Imaging 36(10):1696
  • Lhommel R, van Elmbt L, Goffette P, Van den Eynde M, Jamar F, Pauwels S, Walrand S (2010) Feasibility of 90 Y TOF PET-based dosimetry in liver metastasis therapy using SIR-spheres. Eur J Nucl Med Mol Imaging 37(9):1654–1662
  • Maziere B, Loc’h C, Steinling M, Comar D (1986) Stable labelling of serum albumin microspheres with gallium-68. Int J Radiat Appl Instrum Part A Appl Radiat Isot 37(4):360–361
  • Murthy R, Nunez R, Szklaruk J, Erwin W, Madoff DC, Gupta S, Ahrar K, Wallace MJ, Cohen A, Coldwell DM (2005) Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 25(Suppl 1):S41–S55
  • Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, Omary RA, Salem R (2009) Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 20(9):1121–1130
  • Rodríguez-Fraile M, Arbizu J, Iñarrairaegui M, Martí-Climent J, Quincoces G, Garrastachu P, Domínguez I, Peñuelas I, Sangro B, Richter J (2008) Evaluation of 99mTc-MAA SPECT as a biomarker of liver tumor response to radioembolization with 90-yttrium. Eur J Nucl Med Mol Imaging 35(Suppl 2):S278
  • Rong X, Du Y, Frey EC (2012a) A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to Y-90 bremsstrahlung SPECT imaging. Phys Med Biol 57:3711–3725
  • Rong X, Du Y, Ljungberg M, Rault E, Vandenberghe S, Frey EC (2012b) Development and evaluation of an improved quantitative 90Y bremsstrahlung SPECT method. Med Phys 39:2346–2358
  • Sabet A, Ahmadzadehfar H, Muckle M, Haslerud T, Wilhelm K, Biersack HJ, Ezziddin S (2011) Significance of oral administration of sodium perchlorate in planning liver-directed radioembolization. J Nucl Med 52:1063–1067
  • Salem R, Thurston KG (2006) Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 17:1251–1278
  • Sánchez-Martínez M, Colantes M, Rodriguez-Fraile M, Dominguez-Prado I, Vidal A, Iñarrairaegui M, Bilbao J, Sangro B, Peñuelas I (2012) Fluorine-18 radiolabelling of SIR-spheres as biodistribution surrogate od radiospheres treatment: in vivo micro-PET and in vitro stability studies. Eur J Nucl Med Mol Imaging 39 (Suppl 2):S-168
  • Selwyn R, Avila-Rodriguez M, Converse A, Hampel J, Jaskowiak C, McDermott J, Warner T, Nickles R, Thomadsen B (2007) 18F-labeled resin microspheres as surrogates for 90Y resin microspheres used in the treatment of hepatic tumors: a radiolabeling and PET validation study. Phys Med Biol 52:7397–7408
  • Van de Wiele C, Maes A, Brugman E, D’Asseler Y, De Spiegeleer B, Mees G, Stellamans K (2012) SIRT of liver metastases: physiological and pathophysiological considerations. Eur J Nucl Med Mol Imaging 39:1646–1655
  • van Elmbt L, Vandenberghe S, Walrand S, Pauwels S, Jamar F (2011) Comparison of yttrium-90 quantitative imaging by TOF and non-TOF PET in a phantom of liver selective internal radiotherapy. Phys Med Biol 56:6759–6777
  • Wu SY, Kuo JW, Chang TK, Liu RS, Lee RC, Wang SJ, Lin WJ, Wang HE (2012) Preclinical characterization of 18F-MAA, a novel PET surrogate of 99mTc-MAA. Nucl Med Biol 39:1026–1033
  • Yorke ED, Jackson A, Rosenzweig KE, Braban L, Leibel SA, Ling CC (2005) Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 63:672–682
  • Yu N, Srinivas SM, Difilippo FP, Shrikanthan S, Levitin A, McLennan G, Spain J, Xia P, Wilkinson A (2013) Lung dose calculation with SPECT/CT for 90Yittrium radioembolization of liver cancer. Int J Radiat Oncol Biol Phys 85:834–839